Johnson & Johnson

JNJ • Drug Manufacturers - General

$275.23

— 0.00 (0.00%)

ResultadosÚltimo reporte: 29 mar 2026

PERFIL FAVORABLEAtractivaConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Alta calidad del negocio, con crecimiento y flujo de caja que respaldan el caso. La valoración todavía importa, pero el historial de ratios es favorable.

Capitalización

$672.99B

Crecimiento

7.4%

Flujo de caja

5/5

Tendencia

Stable

Evidencia

Márgenes estables o en mejora · 28.5%Crecimiento positivo de ingresos · 6.7%Flujo de caja libre positivo · 8.11Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 18.81

Datos financieros hasta: 29 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 14 abr 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:36 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$275.23

Change0.00%

Shares Out2.45B

Market Cap$672.99B

Enterprise Value$668.40B

52W Range151.01 - 251.71

Beta0.26

P/E31.99

P/S6.98

P/B8.29

P/FCF37.84

EV/Sales6.94

Price$275.23

Change0.00%

Shares Out2.45B

Market Cap$672.99B

Enterprise Value$668.40B

52W Range151.01 - 251.71

Beta0.26

P/E31.99

P/S6.98

P/B8.29

P/FCF37.84

EV/Sales6.94

EV/EBITDA21.14

EV/FCF37.58

Earnings Yield3.13%

FCF Yield2.64%

Dividend Yield1.87%

Gross Margin72.78%

Oper. Margin27.17%

Profit Margin28.46%

Debt/Eq0.59

Current Ratio1.03

Quick Ratio0.77

Revenue 5Y7.44%

Target$284.79

Target Upside3.47%

Target Median$284.50

Target Range255.00 - 320.00

Volume10.03M

Avg Volume7.83M

EPS Surprise0.02

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

90/100

Fortaleza financiera

Deuda, caja, estabilidad

65/100

Potencial de crecimiento

Ingresos y expansión

63/100

Atractivo del precio

Barata o cara hoy

63/100

Por qué este puntaje▼

Márgenes estables o en mejora · 28.5%Crecimiento positivo de ingresos · 6.7%Flujo de caja libre positivo · 8.11Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 18.81Nivel de deuda manejable · 0.59

Analyst view

Analyst sentiment and price target

JNJ

Analyst sentiment

Based on 40 analyst votes · 2026-09-05

73/100

Bullish

Hold

Bearish

Precio objetivo

2026-06-26

Bajo

$208.00

Promedio

$251.55

Mediana

$255.00

Alto

$283.00

Resumen de la compañía

IPO: 1/2/1962

Industria: Drug Manufacturers - General

P/B i: 8.29

Deuda / Patrimonio i: 0.59

Margen operativo: 27.17%

Margen neto: 28.46%

ROE i: -

ROIC: -

Salud financiera

Puntaje13 / 20

Deuda / Patrimonio: 0.59

Ratio corriente: 1.03

Ratio rápido: 0.77

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Wengel Kathryn E

Transacción: 06/11/2026

VENTA

Cambio

-10,000

Precio

$115.67

Presentación

06/12/2026

Tipo

VENTA

Wengel Kathryn E

Transacción: 06/11/2026

VENTA

Cambio

-10,000

Precio

$241.15

Presentación

06/12/2026

Tipo

VENTA

HEWSON MARILLYN A

Transacción: 06/09/2026

COMPRA

Cambio

—

Precio

Not reported

Presentación

06/11/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Wengel Kathryn E	VENTA	-10,000	$115.67	06/11/2026	06/12/2026
Wengel Kathryn E	VENTA	-10,000	$241.15	06/11/2026	06/12/2026
HEWSON MARILLYN A	COMPRA	—	Not reported	06/09/2026	06/11/2026
Pinto Daniel E	COMPRA	—	Not reported	06/09/2026	06/11/2026
Woods Eugene A.	COMPRA	—	Not reported	06/09/2026	06/11/2026
REED JOHN C	VENTA	-25,255	Not reported	05/01/2026	05/04/2026
REED JOHN C	VENTA	-11,002	$229.85	05/01/2026	05/04/2026
Beckerle Mary C	COMPRA	+975	Not reported	04/23/2026	04/27/2026
Doudna Jennifer A	COMPRA	+975	Not reported	04/23/2026	04/27/2026
HEWSON MARILLYN A	COMPRA	+975	Not reported	04/23/2026	04/27/2026
Johnson Paula A	COMPRA	+975	Not reported	04/23/2026	04/27/2026
Joly Hubert	COMPRA	+975	Not reported	04/23/2026	04/27/2026
McClellan Mark B.	COMPRA	+975	Not reported	04/23/2026	04/27/2026
MORIKIS JOHN G	COMPRA	+1,540	Not reported	04/23/2026	04/27/2026
Pinto Daniel E	COMPRA	+1,712	Not reported	04/23/2026	04/27/2026
WEINBERGER MARK A	COMPRA	+975	Not reported	04/23/2026	04/27/2026
West Nadja	COMPRA	+975	Not reported	04/23/2026	04/27/2026
Woods Eugene A.	COMPRA	+975	Not reported	04/23/2026	04/27/2026
Woods Eugene A.	COMPRA	—	Not reported	03/10/2026	03/12/2026
Pinto Daniel E	COMPRA	—	Not reported	03/10/2026	03/12/2026

Sobre la compañía

Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Fuente - Link

Competidores

ABBV AMGN AZN GILD MRK NVO NVS PFE SNY UNH

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Johnson & Johnson Is Boring Which Makes Its Dividend Nearly Perfect.

Sixty-four straight years of dividend growth sounds like a headline, but the real story is what keeps that streak alive even as one of JNJ's biggest drugs faces a brutal competitive hit.

24/7 Wall Street

Evolve Private Wealth LLC Has $7.96 Million Holdings in Johnson & Johnson $JNJ

Evolve Private Wealth LLC lessened its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 27.5% during the quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,341 shares of the company's stock after selling 11,894 shares during the period. Johnson and

Defense World

GQG Partners LLC Sells 7,292,131 Shares of Johnson & Johnson $JNJ

GQG Partners LLC cut its position in shares of Johnson and Johnson (NYSE: JNJ) by 99.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 25,158 shares of the company's stock after selling 7,292,131 shares during the period. GQG Partners

Defense World

Compass Financial Management LLC Makes New Investment in Johnson & Johnson $JNJ

Compass Financial Management LLC purchased a new stake in Johnson and Johnson (NYSE: JNJ) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 5,572 shares of the company's stock, valued at approximately $1,417,000. Several other large investors also recently

Defense World

Emerald Investment Advisers LLC Purchases 7,121 Shares of Johnson & Johnson $JNJ

Emerald Investment Advisers LLC raised its position in shares of Johnson and Johnson (NYSE: JNJ) by 28.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 32,530 shares of the company's stock after acquiring an additional 7,121 shares during the quarter. Emerald Investment

Defense World

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-04-14	2.68	2.7	0.02
2026-01-21	2.46	2.46	0
2025-10-14	2.76	2.8	0.04
2025-07-16	2.68	2.77	0.09
2025-04-15	2.58	2.77	0.19
2025-01-22	1.99	2.04	0.05
2024-10-15	2.21	2.42	0.21
2024-07-17	2.71	2.82	0.11
2024-04-16	2.64	2.71	0.07
2024-01-23	2.27	2.29	0.02
2023-10-17	2.52	2.66	0.14
2023-07-20	2.61	2.8	0.19